The endogenous cannabinoid system in schizophrenia

doi:10.1017/CBO9780511543630.011

9 - The endogenous cannabinoid system in schizophrenia

Published online by Cambridge University Press: 07 December 2009

Suresh Sundram ,

Brian Dean and

David Copolov

Edited by

David Castle and

Robin Murray

Show author details

Suresh Sundram: Affiliation:
Mental Health Research Institute, Victoria, Australia
Brian Dean: Affiliation:
Mental Health Research Institute, Victoria, Australia
David Copolov: Affiliation:
Mental Health Research Institute, Victoria, Australia
David Castle: Affiliation:
Mental Health Research Institute, Melbourne
Robin Murray: Affiliation:
Institute of Psychiatry, London

Book contents

Get access

Summary

The human endogenous cannabinoid system is an appealing target in the investigation of schizophrenia. This is both because of clinical studies supporting the association between cannabis use and schizophrenia as well as the capacity of Δ9-tetrahydrocannabinol (Δ9-THC) to induce psychotic symptoms in non-psychotic individuals (see Chapters 3–5). Only since the recent elucidation of the endogenous cannabinoid system have direct investigations into its potential role in schizophrenia and other neuropsychiatric disorders become possible. The endocannabinoid system contains the cannabinoid CB1, CB1A and CB2 receptors; the endogenous cannabinoids (most importantly, anandamide, 2-arachidonylglycerol (2-AG) and palmitoylethanolamide), their respective synthetic and degradative enzymes and a transport process. This chapter provides an overview of the human endogenous cannabinoid system, focusing specifically on those aspects relevant to schizophrenia (see also Chapters 1 and 2 for a broader overview), and then reviews studies concerning this system in schizophrenia.

The human endogenous cannabinoid system

The Cannabinoid CB1 receptor in the brain

The first component of the human endogenous cannabinoid system to be identified was the CB1 receptor (Herkenham et al., 1990). The gene for this receptor is located on region q14–q15 of chromosome 6 (Hoehe et al., 1991) and encodes for a 472-amino-acid protein (Matsuda et al., 1990). This receptor has seven trans-membrane-spanning domains and interacts with guanine nucleotide-binding proteins (G proteins) as part of its signal transduction mechanism, placing it within the superfamily of G protein-coupled receptors.

Information

Type: Chapter
Information: Marijuana and Madness
Psychiatry and Neurobiology
, pp. 127 - 141

DOI: https://doi.org/10.1017/CBO9780511543630.011 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Amara, S. G. and Kuhar, M. J. (1993). Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci., 16, 73–93CrossRef Google Scholar PubMed

Ameri, A. (1999). The effects of cannabinoids on the brain. Progr. Neurobiol., 58, 315–348CrossRef Google Scholar

Beltramo, M., Stella, N., Calignano, A.et al. (1997). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science, 277, 1094–1097CrossRef Google Scholar PubMed

Bisogno, T., Berrendero, F., Ambrosino, G.et al. (1999). Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun., 256, 377–380CrossRef Google Scholar PubMed

Bonnin, A., Miguel, R., Castro, J. G., Ramos, J. A. and Fernandez-Ruiz, J. J. (1996). Effects of perinatal exposure to delta 9-tetrahydrocannabinol on the fetal and early postnatal development of tyrosine hydroxylase-containing neurons in rat brain. J. Mol. Neurosci., 7, 291–308CrossRef Google Scholar PubMed

Breivogel, C. S., Griffin, G., Di, M. V. and Martin, B. R. (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol., 60, 155–163CrossRef Google Scholar

Buhler, B., Hambrecht, M., Loffler, W., an, H. W. and Hafner, H. (2002). Precipitation and determination of the onset and course of schizophrenia by substance abuse – a retrospective and prospective study of 232 population-based first illness episodes. Schizophr. Res., 54, 243–251CrossRef Google Scholar PubMed

Comings, D. E., Muhleman, D., Gade, R.et al. (1997). Cannabinoid receptor gene (CNR1): association with ⅰ.ⅴ. drug use. Mol. Psychiatry, 2, 161–168CrossRef Google Scholar PubMed

Cravatt, B. F., Giang, D. K., Mayfield, S. P.et al. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 384, 83–87CrossRef Google Scholar PubMed

Dawson, E. (1995). Identification of a polymorphic triplet marker for the brain cannabinoid receptor gene: use in linkage and association studies of schizophrenia. Psych. Gen., 5, s50–s51Google Scholar

Dean, B., Sundram, S., Bradbury, R., Scarr, E. and Copolov, D. (2001). Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience, 103, 9–15CrossRef Google Scholar

Dean, B., Bradbury, R. and Copolov, D. L. (2003). Cannabis-sensitive dopaminergic markers in postmortem CNS: changes in schizophrenia. Biol. Psychiatry, 53, 585–592CrossRef Google Scholar

Devane, W. A., Hanus, L., Breuer, A.et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946–1949CrossRef Google Scholar PubMed

Di Marzo, V., Fontana, A., Cadas, H.et al. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 372, 686–691CrossRef Google Scholar PubMed

Di Marzo, V., Breivogel, C. S., Tao, Q.et al. (2000). Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J. Neurochem., 75, 2434–2444CrossRef Google Scholar

Dinh, T. P., Carpenter, D., Leslie, F. M.et al. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl Acad. Sci. USA, 99, 10819–10824CrossRef Google Scholar PubMed

Egertova, M. and Elphick, M. R. (2000). Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. J. Comp. Neurol., 422, 159–1713.0.CO;2-1>CrossRef Google Scholar PubMed

Elphick, M. R. and Egertova, M. (2001). The neurobiology and evolution of cannabinoid signalling. Philos. Trans. R. Soc. Lond. B Biol. Sci., 356, 381–408CrossRef Google Scholar PubMed

Emrich, H. M., Leweke, F. M. and Schneider, U. (1997). Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol. Biochem. Behav., 56, 803–807CrossRef Google Scholar PubMed

Felder, C. C., Nielsen, A., Briley, E. M.et al. (1996). Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett., 393, 231–235CrossRef Google Scholar PubMed

Gadzicki, D., Muller-Vahl, K. and Stuhrmann, M. (1999). A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol. Cell Probes, 13, 321–323CrossRef Google Scholar PubMed

Giuffrida, A., Parsons, L. H., Kerr, T. M.et al. (1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neurosci., 2, 358–363CrossRef Google Scholar PubMed

Glass, M., Faull, R. L. and Dragunow, M. (1993). Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience, 56, 523–527CrossRef Google Scholar PubMed

Glass, M., Dragunow, M. and Faull, R. L. (1997). Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the foetal, neonatal and adult human brain. Neuroscience, 77, 299–318CrossRef Google Scholar

Glass, M., Dragunow, M. and Faull, R. L. (2000). The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience, 97, 505–519CrossRef Google Scholar PubMed

Goparaju, S. K., Ueda, N., Yamaguchi, H. and Yamamoto, S. (1998). Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett., 422, 69–73CrossRef Google Scholar PubMed

Hambrecht, M. and Hafner, H. (2000). Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust. NZ J. Psychiatry, 34, 468–475CrossRef Google Scholar

Harrison, P. J. (1999). The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain, 122 (Pt 4), 593–624CrossRef Google Scholar PubMed

Herkenham, M., Lynn, A. B., Little, M. D.et al. (1990). Cannabinoid receptor localization in brain. Proc. Natl Acad. Sci. USA, 87, 1932–1936CrossRef Google Scholar PubMed

Hernandez, M. L., Garcia-Gil, L., Berrendero, F., Ramos, J. A. and Fernandez-Ruiz, J. J. (1997). Delta 9-tetrahydrocannabinol increases activity of tyrosine hydroxylase in cultured fetal mesencephalic neurons. J. Mol. Neurosci., 8, 83–91CrossRef Google Scholar PubMed

Hillard, C. J. (2000). Endocannabinoids and vascular function. J. Pharmacol. Exp. Ther., 294, 27–32Google Scholar PubMed

Hoehe, M. R., Caenazzo, L., Martinez, M. M.et al. (1991). Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14–q15. New Biol., 3, 880–885Google Scholar PubMed

Hoffman, A. F. and Lupica, C. R. (2000). Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J. Neurosci., 20, 2470–2479CrossRef Google Scholar PubMed

Howlett, A. C., Barth, F., Bonner, T. I.et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161–202CrossRef Google Scholar PubMed

Khantzian, E. J. (1997). The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harvard Rev. Psychiatry, 4, 231–244CrossRef Google Scholar PubMed

Leroy, S., Griffon, N., Bourdel, M. C.et al. (2001). Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am. J. Med. Genet., 105, 749–752CrossRef Google Scholar PubMed

Leweke, F. M. (2002). Elevated CSF endocannabinoid levels in schizophrenic patients versus controls. Int. J. Neuropsychopharmacol., 5 [S1], s47Google Scholar

Leweke, F. M., Schneider, U., Thies, M., Munte, T. F. and Emrich, H. M. (1999a). Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology (Berl.), 142, 230–235CrossRef Google Scholar

Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M. and Piomelli, D. (1999b). Elevated endogenous cannabinoids in schizophrenia. Neuroreport, 10, 1665–1669CrossRef Google Scholar

Mailleux, P., Parmentier, M. and Vanderhaeghen, J. J. (1992). Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligo-nucleotides. Neurosci. Lett., 143, 200–204CrossRef Google Scholar

Matsuda, L. (1997). Molecular aspects of cannabinoid receptors. Crit. Rev. Neurobiol., 11, 143–166CrossRef Google Scholar PubMed

Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. and Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561–564CrossRef Google Scholar PubMed

Meltzer, H. Y. and Stahl, S. M. (1976). The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull., 2, 19–76CrossRef Google Scholar PubMed

Perlstein, W. M., Carter, C. S., Noll, D. C. and Cohen, J. D. (2001). Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. Am. J. Psychiatry, 158, 1105–1113CrossRef Google Scholar

Pistis, M., Porcu, G., Melis, M., Diana, M. and Gessa, G. L. (2001). Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur. J. Neurosci., 14, 96–102CrossRef Google Scholar PubMed

Porter, A. C. and Felder, C. C. (2001). The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol. Ther., 90, 45–60CrossRef Google Scholar PubMed

Rakhshan, F., Day, T. A., Blakely, R. D. and Barker, E. L. (2000). Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL- 2H3 cells. J. Pharmacol. Exp. Ther., 292, 960–967Google Scholar PubMed

Sakurai-Yamashita, Y., Kataoka, Y., Fujiwara, M., Mine, K. and Ueki, S. (1989). Delta 9-tetrahydrocannabinol facilitates striatal dopaminergic transmission. Pharmacol. Biochem. Behav., 33, 397–400CrossRef Google Scholar PubMed

Schlicker, E. and Kathmann, M. (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci., 22, 565–572CrossRef Google Scholar PubMed

Schneider, U., Leweke, F. M., Niemcyzk, W.et al. (1996). Impaired binocular depth inversion in patients with alcohol withdrawal. J. Psychiatr. Res., 30, 469–474CrossRef Google Scholar PubMed

Schneider, U., Borsutzky, M.et al. (2002). Reduced binocular depth inversion in schizophrenic patients. Schizophr. Res., 53, 101–108CrossRef Google Scholar PubMed

Shire, D., Carillon, C., Kaghad, M.et al. (1995). An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem., 270, 3726–3731CrossRef Google Scholar PubMed

Sipe, J. C., Chiang, K., Gerber, A. L., Beutler, E. and Cravatt, B. F. (2002). A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc. Natl Acad. Sci. USA, 99, 8394–8399CrossRef Google Scholar PubMed

Stella, N., Schweitzer, P. and Piomelli, D. (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature, 388, 773–778CrossRef Google Scholar PubMed

Sundram, S., Bradbury, R., Copolov, D. L. and Dean, B. (2000). Clozapine differentially and reversibly alters cannabinoid CB1 receptor binding in the rat nucleus accumbens. Int. J. Neuropsychopharmacol., 3 [S1], S132Google Scholar

Tsai, S. J., Wang, Y. C. and Hong, C. J. (2000). Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatr. Genet., 10, 149–151CrossRef Google Scholar

Ujike, H., Takaki, M., Nakata, K.et al. (2002). CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol. Psychiatry, 7, 515–518CrossRef Google Scholar PubMed

Voruganti, L. N., Slomka, P., Zabel, P., Mattar, A. and Awad, A. G. (2001). Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res., 107, 173–177CrossRef Google Scholar

Westlake, T. M., Howlett, A. C., Bonner, T. I., Matsuda, L. A. and Herkenham, M. (1994). Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience, 63, 637–652CrossRef Google Scholar

Wilson, R. I. and Nicoll, R. A. (2001). Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature, 410, 588–592CrossRef Google Scholar PubMed

Wilson, R. I. and Nicoll, R. A. (2002). Endocannabinoid signaling in the brain. Science, 296, 678–682CrossRef Google Scholar

Yang, H. Y., Karoum, F., Felder, C.et al. (1999). GC/MS analysis of anandamide and quantification of N-arachidonoylphosphatidylethanolamides in various brain regions, spinal cord, testis, and spleen of the rat. J. Neurochem., 72, 1959–1968CrossRef Google Scholar PubMed